Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
Yunovias pipeline includes several candidates, such as ID110521156, an oral synthetic new drug for diabetes and obesity, ID120040002, a peptic ulcer treatment in the potassium-competitive gastric acid secretion inhibitor (P-CAB) series, ID119040338, a Parkinson's disease treatment targeting adenosine A1 and A2A receptors, and ID119031166, a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
Wegovy is a higher-dose formulation of semaglutide specifically approved for weight management in individuals without diabetes
Molecular Handle Working Together Mosquitoes and DDT Exploring the Structure Glutathione Transferase Glutathione transferases also play a central role in detoxification of drugs
Manage Stress & Maintain a CleanMIND Chronic stress can significantly impact intestinal permeability and upset the delicate balance of gut microbes
In August 2024, Novo Nordisk, one of the pharmaceutical leaders in diabetes and obesity care, launched its weight-loss drug Wegovy in Australia, intended for chronic weight management in patients with obesity or overweight with related conditions like diabetes or hypertension, Wegovy entered the market amid ongoing Ozempic supply concerns
These side effects can be minimised by making subtle changes to your diet, or even using over the counter remedies, explains Michael Sam-Yorke, pharmacist, clinician and independent prescriber
&srotate=0)
US$ 20.49
US$ 29.81
US$ 20.99
US$ 22.59
US$ 22.64
US$ 24.27
US$ 24.52
US$ 29.31
